 New Oxbryta voxelotor Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease New Oxbryta voxelotor Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease 